In the post-hoc analysis of 133 patients with RAS/BRAF-WT CRC, ctDNA tracking showed a trend towards a higher prevalence of acquired mutations associated with resistance to EGFR antibody in patients (n = 11; 15.3%) randomized to the bevacizumab arm than patients in the cetuximab arm (n = 5; 8.2%) (OR = 2.0; P = 0.29). This evidence concerns the gene BRAF and colorectal carcinoma.